Zobrazeno 1 - 10
of 129
pro vyhledávání: '"J. P. Maire"'
Autor:
Erwan de Monès del Pujol, Valérie Franco-Vidal, Judith Kouassi, J.-P. Maire, Vincent Darrouzet
Publikováno v:
Otology & Neurotology. 35:911-917
OBJECTIVES To describe difficulties in diagnosing meningeal carcinomatosis of the internal auditory meatus (IAM-MC). STUDY DESIGN Retrospective case review. SETTING Tertiary skull base surgery referral center. PATIENTS A series of six cases of patien
Recommandations pour la délinéation des aires ganglionnaires pelviennes dans le cancer du canal anal
Publikováno v:
Cancer/Radiothérapie. 17:566-570
Squamous cell anal cancer is a rare malignancy, its incidence increases due to higher exposure of the young adults to risk factors. The current management is based on chemoradiotherapy, which is highly effective and achieves locoregional control but
Autor:
Valérie Franco-Vidal, Sandrine Eimer, J.-P. Maire, François San Galli, Aymeri Huchet, Sigolène Galland-Girodet, Vincent Darrouzet
Publikováno v:
Case Reports in Otolaryngology
Case Reports in Otolaryngology, Vol 2013 (2013)
Case Reports in Otolaryngology, Vol 2013 (2013)
Inflammatory myofibroblastic tumors (IMTs) are rare benign clinical and pathological entities. IMTs have been described in the lungs, abdomen, retroperitoneum, and extremities but rarely in the head and neck region. A 38-year-old man presented with h
Publikováno v:
Cancer/Radiothérapie. 16:S79-S89
Meningiomas are the most common non-malignant tumours of the brain. Gross-total resection remains the preferred treatment, if achievable without morbidity. Radiation therapy is advocated for inoperable, incompletely resected, or recurrent grade 1 tum
Autor:
Dominique Liguoro, Vincent Darrouzet, Valérie Franco-Vidal, Sandrine Eimer, Clotilde Perret, Aymeri Huchet, John Goudakos, Konstantinos Markou, J.-P. Maire
Publikováno v:
American Journal of Otolaryngology. 33:168-173
Objective Malignant transformation of vestibular schwannoma is considered a rare clinical entity. Radiotherapy, as a treatment option for vestibular schwannoma, is regarded as a potential risk factor for secondary malignancy. Recently, radiotherapy w
Autor:
I, Baldi, A, Gruber, A, Alioum, E, Berteaud, P, Lebailly, A, Huchet, T, Tourdias, G, Kantor, J P, Maire, A, Vital, H, Loiseau, J R, Vignes
Publikováno v:
Neuro-Oncology. 13:1370-1378
An increase in the incidence of CNS tumors has been observed in many countries in the last decades. The reality of this trend has been much debated, as it has happened during a period when computer-assisted tomography and MRI have dramatically improv
Autor:
Yazid Belkacemi, Michèle Allard, Thomas Tourdias, Sandrine Eimer, Philippe Fernandez, Aymeri Huchet, J.-P. Maire, Hugues Loiseau, R. Trouette
Publikováno v:
Cancer/Radiothérapie. 13:747-757
By allowing an earlier diagnosis and a more exhaustive assessment of extension of the disease, the tomography by emission of positrons (TEP) transforms the care of numerous cancers. At present, (18)F-fluorodesoxyglucose ([(18)F]-FDG) imaging appears
Autor:
M. Capdepont, Christophe Laurent, D. Smith, G. Kantor, J.-P. Maire, Véronique Vendrely, H. Tournat, B. Cherciu
Publikováno v:
Cancer/Radiothérapie. 12:336-342
Resume Objectif Il n’y a pas de consensus quant au traitement de la tumeur rectale primitive en situation metastatique. L’interet de la radiotherapie rectale est discute au cas par cas. Patients et methodes Trente-sept patients atteints de tumeur
Publikováno v:
Revue Neurologique. 164:531-541
Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors. The prognosis of these tumors depends on multiple factors such as age at diagnosis, Karnofsky score, histopathology, biology and treatments. Radiotherapy (RT) plays an
Autor:
K. Hoang Xuan, Luc Taillandier, A. Desjardins, Stéphanie Cartalat-Carel, I. Catry-Thomas, J-P. Maire, O. L. Chinot, Bruno Chauffert, A. Thiebaut, S. Guiu, C. Deville, Jérôme Honnorat, Jean-Sébastien Guillamo, Pierre Fumoleau, F. Capelle, Pierre-Yves Dietrich, B. Guiu, S. Taillibert
Publikováno v:
Revue neurologique, Vol. 164, No 6-7 (2008) pp. 588-94
INTRODUCTION: Les chimiothérapies de seconde ligne dans les gliomes de haut grade récidivants sont décevantes. Des résultats spectaculaires avec la combinaison originale d'un antiangiogénique (bevacizumab, anticorps monoclonal anti-VEGF) et d'un